Clinical trial
The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)
NCT00292877 · St. Joseph's Healthcare Hamilton, Other · Completed
Key facts
| NCT number | NCT00292877 |
|---|---|
| Title | The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563) |
| Official title | The Effects of a Humanized Anti-IL-5 Monoclonal Antibody (SB-240563) on Asthma Control, Airway Eosinophilia and the Degree to Which Corticosteroid Treatment Can be Reduced to Maintain Control |
| Lead sponsor | St. Joseph's Healthcare Hamilton, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | SB-240563 (Mepolizumab) |
| Enrollment | 20 |
| Start date | Jan 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Feb 16, 2006 |
| Last update posted | Jan 24, 2011 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: